Category News

Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd.and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.today announced a significant strategic partnership for the development and eventual commercial delivery of…

Read MoreTeva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy

BMS Presents Transcend FL Data: Breyanzi Shows Durable Responses in Marginal Zone Lymphoma

Bristol Myers Squibb Presents Positive Transcend FL Data Highlighting Durable Responses with Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma Bristol Myers Squibb today announced the first disclosure of the primary analysis results from the marginal zone lymphoma (MZL) cohort…

Read MoreBMS Presents Transcend FL Data: Breyanzi Shows Durable Responses in Marginal Zone Lymphoma

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated and extensive follow-up data from the Phase 1 portion of…

Read MoreIntellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients

Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update for ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is currently the only U.S.…

Read MoreSarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients

EAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study

Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. today presented new and significant data demonstrating the superiority…

Read MoreEAACI: Dupixent Supersedes Xolair in CRS w/ Nasal Polyps and Asthma Phase 4 Head-to-Head Study

Roche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients

Roche Suspends Elevidys Dosing in Non-Ambulatory DMD Patients Amid Safety Concerns Roche today announced a significant update to its dosing guidelines for Elevidys™ (delandistrogene moxeparvovec), following a careful reassessment of its benefit-risk profile in non-ambulatory patients with Duchenne muscular dystrophy…

Read MoreRoche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients